CAMKK2 and Alzheimer disease: Another possibility that cannot be excluded is that up to 50% of patients with PD also develop AD pathologies (Aβ plaques and MAPT-containing neurofibrillary tangles) (Irwin et al., 2013), potentially contributing to the observed CAMKK2 reduction in the PD patient cohorts.